Revvity announced 4% year-over-year revenue growth in Q2 2025, driven by gains in diagnostics and life sciences segments. Revenues totaled $720.3 million, beating estimates, with diagnostics up 3% and life sciences up 5%. The company increased R&D spending by 11% while lowering selling and administrative expenses modestly. Revvity slightly raised full-year 2025 revenue outlook but lowered EPS guidance due to tariff headwinds and other factors. The firm continues investing in innovation while navigating supply chain challenges.